title: [Preoperative chemotherapy with TS-1 and low dose cisplatin for oral squamous cell carcinoma patients--a preliminary study].
abstract: We investigated the histological response and toxicities of combination chemotherapy with TS-1 and low-dose CDDP, and evaluated the usefulness of this regimen as a preoperative chemotherapy. Fourteen patients were enrolled in this study (two men and 12 women, with a mean age of 54.5 years). Patients were administered TS-1 80 mg/m2/day (days 1-14) and CDDP 5 mg/m2/day (days 1-5, 8-12) and followed by radical surgery or biopsy within 2 weeks. Ten patients completed 1 cycle of chemotherapy, two received 0.5 cycle and two others 1.5 cycle. The histological antitumor effects were evaluated with Ohboshi & Shimosato's classification using surgical or biopsy specimens of primary tumors. The response rate was 64.3% in clinical evaluation and 50.0% in histological evaluation. The number of patients who showed CR were 7/14 (50.0%) and 5/14 (35.7%) by histological and clinical evaluation, respectively. Two patients showed grade 3 neutropenia. Almost all patients revealed no or mild toxicities. TS-1 with low-dose CDDP represents a highly effective antitumor activity and mild toxicities. Especially, the CR rate was very high. These data suggested that this regimen was useful to avoid surgery or to realize minimal surgery for oral squamous cell carcinoma patients.
authors.affiliation: Second Dept. of Oral and Maxillofacial Surgery, Osaka University/Graduate School of Dentistry,
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Nakazawa
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Ohnishi
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Chisoku
authors.forename: Wataru
authors.initials: W
authors.lastname: Katagiri
authors.forename: Toshihide
authors.initials: T
authors.lastname: Doi
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takase
authors.forename: Shumpei
authors.initials: S
authors.lastname: Yui
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Miwa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Fukuda
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Kishino
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Yura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000601:surgery; D009503:Neutropenia / Q000139:chemically induced; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin